Charles River Laboratories International, Inc. $CRL Shares Acquired by Teacher Retirement System of Texas

Teacher Retirement System of Texas increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 36.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 10,556 shares of the medical research company’s stock after purchasing an additional 2,822 shares during the period. Teacher Retirement System of Texas’ holdings in Charles River Laboratories International were worth $1,652,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Jones Financial Companies Lllp increased its holdings in shares of Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,074 shares during the period. Empowered Funds LLC acquired a new stake in Charles River Laboratories International during the 1st quarter valued at $418,000. Farther Finance Advisors LLC boosted its stake in shares of Charles River Laboratories International by 175.8% during the second quarter. Farther Finance Advisors LLC now owns 615 shares of the medical research company’s stock valued at $93,000 after acquiring an additional 392 shares during the last quarter. HB Wealth Management LLC purchased a new position in shares of Charles River Laboratories International during the 2nd quarter worth $306,000. Finally, Patriot Financial Group Insurance Agency LLC increased its stake in Charles River Laboratories International by 19.3% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 2,035 shares of the medical research company’s stock valued at $309,000 after purchasing an additional 329 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CRL shares. Argus set a $200.00 price target on Charles River Laboratories International in a research report on Monday, November 17th. TD Cowen reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Thursday, January 22nd. Evercore ISI upped their price objective on Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, January 23rd. Finally, William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $209.46.

Charles River Laboratories International Trading Down 0.5%

NYSE:CRL opened at $210.60 on Friday. The stock’s 50-day moving average is $202.24 and its two-hundred day moving average is $178.41. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The stock has a market cap of $10.37 billion, a PE ratio of -135.00, a price-to-earnings-growth ratio of 6.35 and a beta of 1.61. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The firm’s revenue was down .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.59 earnings per share. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.